SCOTTSDALE, Ariz., Oct. 18, 2023 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (NASDAQ: LFST), one of the nation’s largest providers of outpatient mental health care, will issue its third quarter earnings release before the market opens on Wednesday, November 8, 2023.
LifeStance will host a live earnings conference call to discuss third quarter results on November 8, 2023, at 8:30 a.m. (Eastern time). To participate in the call, please dial 1-800-715-9871, domestically, or 1-646-307-1963, internationally, and use conference ID 3827662, or ask to be joined into the LifeStance call.
A real-time audio webcast can be accessed via the Events and Presentations section of the LifeStance Investor Relations website (https://investor.lifestance.com), where related materials will be posted prior to the conference call.
A replay of the webcast will be available after the conclusion of the conference call and can be accessed on the LifeStance Investor Relations website.
About LifeStance Health
Founded in 2017, LifeStance (NASDAQ: LFST) is reimagining mental health. We are one of the nation’s largest providers of virtual and in-person outpatient mental health care for children, adolescents and adults experiencing a variety of mental health conditions. Our mission is to help people lead healthier, more fulfilling lives by improving access to trusted, affordable and personalized mental health care. LifeStance employs approximately 6,100 psychiatrists, advanced practice nurses, psychologists and therapists and operates across 33 states and approximately 600 centers. To learn more, please visit www.LifeStance.com.
| Last Trade: | US$5.16 |
| Daily Change: | 0.12 2.38 |
| Daily Volume: | 1,499,737 |
| Market Cap: | US$2.010B |
August 26, 2025 August 07, 2025 May 07, 2025 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
